12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 23.0% to $0.32 during Monday’s after-market session. The market value of their…
Regulus Therapeutics Advances To Cohort 4 Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Regulus Therapeutics (NASDAQ:RGLS) stock increased by 12.4% to $1.45 during Thursday’s after-market session. The company’s market cap…
Analyst Expectations for Regulus Therapeutics’s Future
Within the last quarter, Regulus Therapeutics (NASDAQ:RGLS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease
Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 70.6% to $5.29 during Wednesday’s pre-market session. The company’s market…
Expert Ratings for Regulus Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Regulus Therapeutics (NASDAQ:RGLS) stock. These analysts…
Regulus Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Advanced Health (NASDAQ:AHI) stock increased by 143.2% to $1.8 during Wednesday’s pre-market session. The market value of…
Regulus Therapeutics Announces Update On Preclinical Studies In Amyotrophic Lateral Sclerosis In Collaboration With Researchers From Harvard’s Brigham And Women’s Hospital
Program advances to lead compound evaluation in preclinical in vivo models
Preliminary data for in vivo studies are expected in second half of 2023
SAN DIEGO, June 20, 2023 /PRNewswire/ -- Regulus